NVAX News

Novavax to Participate in Jefferies London Healthcare Conference

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Novavax Announces Progress on Sanofi Agreement

Novavax Announces Convertible Debt Refinancing

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026